SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

#3417

Introduction: SARS-CoV-2 (COVID19) vaccinations have shown high efficacy. Therefore, increased chances exist that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or radionuclide imaging for Neuroendocrine Tumors (NETs) may have being recently vaccinated.

Aim(s): To report post-PRRT and diagnostic radionuclide imaging findings in patients with NETs, following COVID19 vaccination.

Materials and methods: We report two patients- Patient A: Grade 2 gastric NET with liver metastases, who received [177Lu] Lu-DOTA-TATE; and Patient B: Grade 2 pancreatic NET with hepatic, and mesenteric nodal metastases who had [68Ga]Ga-DOTA-TATE PET/CT imaging, following COVID19 vaccination.

Conference:

Presenting Author: Kolade O

Authors: Kolade O, Ayeni A, Brink A, Steyn R, Prasad V,

Keywords: COVID-19, SARS-CoV-2, Lu-177 DOTATATE, Ga-68 DOTANOC, Vaccination, PRRT, Neuroendocrine Tumor,